百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

已收盘 03-03 16:08:29

178.400

-6.600

-3.57%

最高188.700	最低177.700	成交量595.74万
今开188.400	昨收185.000	日振幅5.95%
总市值2,749亿	流通市值2,544亿	总股本15.41亿
成交额10.76亿	换手率0.42%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":178.4,"timestamp":1772525309005,"preClose":185,"halted":0,"volume":5957403,"delay":0,"changeRate":-0.035675675675675644,"floatShares":1426000000,"shares":1541000000,"eps":1.4836215984070587,"marketStatus":"已收盘","change":-6.6,"latestTime":"03-03 16:08:29","open":188.4,"high":188.7,"low":177.7,"amount":1076187972,"amplitude":0.059459,"askPrice":178.4,"askSize":8300,"bidPrice":178.3,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.4836215984070587,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772587800000},"marketStatusCode":5,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":185,"openAndCloseTimeList":[[1772501400000,1772510400000],[1772514000000,1772524800000]],"volumeRatio":1.220954,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"BOM.HK","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":234.99,"timestamp":1772521200000,"preClose":250.84,"halted":0,"volume":5478500,"delay":0,"premium":"-32.91"},"impliedVol":0.4213,"impliedVolPercentile":0.7586},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2616316707","title":"交银国际：百济神州(06160)上季产品销售强势 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2616316707","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616316707?lang=zh_cn&edition=full","pubTime":"2026-03-03 15:09","pubTimestamp":1772521742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，百济神州去年第四季泽布替尼销售额11亿美元(下同)，同比及按季分别升38%及10%，美国销售额8.45亿，同比及按季分别升37%及14%。在1LCLL患者中，泽布在BTK品类中的份额约占一半、在所有治疗药物中约占四分之一。公司指引2026年收入62亿至64亿，GAAP经营费用47亿至49亿元，毛利率在80%区间的高位，non-GAAP净利润14亿至15亿元，维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","06160","688235"],"gpt_icon":0},{"id":"2616783391","title":"国金证券：维持百济神州(06160)“买入”评级 早研管线步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2616783391","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616783391?lang=zh_cn&edition=full","pubTime":"2026-03-03 10:36","pubTimestamp":1772505397,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，维持百济神州“买入”评级。公司核心产品高速放量，研发管线有望迎来密集催化。国金证券主要观点如下：业绩简评2026年2月26日公司发布2025年业绩快报，全年实现总收入53亿美元，实现GAAP净利润2.87亿美元;其中25Q4实现总收入15亿美元，实现GAAP净利润6650万美元。风险提示商业化进展不及预期风险、市场竞争加剧风险、临床试验进展不及预期风险、产品上市审评进展不及预期风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2616360737","title":"【机构调研记录】摩根士丹利基金调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2616360737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616360737?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:10","pubTimestamp":1772496658,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月2日披露的机构调研信息，摩根士丹利基金近期对1家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：公司在2025年实现净利润和正向自由现金流，经营活动净现金达11亿美元，自由现金流为正。摩根士丹利基金成立于2003年，截至目前，资产管理规模335.08亿元，排名102/212；资产管理规模335.06亿元，排名90/212；管理公募基金数70只，排名88/212；旗下公募基金经理13人，排名95/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300006402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","LU1719994722.HKD","BK1161","LU2328871848.SGD","LU0588546209.SGD","LU1969619763.USD","LU1251922891.USD","06160","LU1770034418.SGD","LU1303224171.USD","BK0239","BK1588","BK1583","BK1500","688235"],"gpt_icon":0},{"id":"2616360223","title":"【机构调研记录】工银瑞信基金调研维尔利、百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2616360223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616360223?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:10","pubTimestamp":1772496653,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月2日披露的机构调研信息，工银瑞信基金近期对2家上市公司进行了调研，相关名单如下：1）维尔利 调研纪要：公司加快推动以科技为核心动力，助力生物能源和工业服务为核心的战略转型。2）百济神州 调研纪要：公司在2025年实现净利润和正向自由现金流，经营活动净现金达11亿美元，自由现金流为正。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300006395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","LU1969619763.USD","LU1719994722.HKD","BK1588","LU1303224171.USD","LU0588546209.SGD","BK0218","BK0077","LU1251922891.USD","300190","BK0150","06160","BK1583","BK0135","LU0307460666.USD","LU2328871848.SGD","688235","BK1500","LU1770034418.SGD"],"gpt_icon":0},{"id":"2616360201","title":"【机构调研记录】光大保德信基金调研百济神州、虹软科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2616360201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616360201?lang=zh_cn&edition=full","pubTime":"2026-03-03 08:10","pubTimestamp":1772496633,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及3月2日披露的机构调研信息，光大保德信基金近期对2家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：公司在2025年实现净利润和正向自由现金流，经营活动净现金达11亿美元，自由现金流为正。2）虹软科技 调研纪要：存储涨价会倒逼行业转向价值战，提升高端机型占比，虹软可发挥软件优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300006368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","BK0239","LU2328871848.SGD","LU0307460666.USD","BK1588","LU1719994722.HKD","LU0588546209.SGD","688235","06160","LU1969619763.USD","BK1500","LU1770034418.SGD","BK1161","LU1251922891.USD","BK1583","BK0231","688088"],"gpt_icon":0},{"id":"2616335380","title":"每日卖空追踪 | 百济神州 03月02日卖空量成交58.03万股，卖空比例为11.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616335380?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:30","pubTimestamp":1772440239,"startTime":"0","endTime":"0","summary":"百济神州北京时间03月02日，跌3.8%，卖空量成交58.03万股，较上一交易日减少57.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163618a730c9ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302163618a730c9ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1251922891.USD","LU1303224171.USD","LU1719994722.HKD","BK1500","LU0307460666.USD","LU2328871848.SGD","BK1588","LU0588546209.SGD","LU1969619763.USD","BK1583","LU1770034418.SGD","BK1161","06160"],"gpt_icon":0},{"id":"2616538865","title":"【券商聚焦】招银国际：AI将改变创新药物研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2616538865","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616538865?lang=zh_cn&edition=full","pubTime":"2026-03-02 14:40","pubTimestamp":1772433633,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际表示，MSCI中国医疗指数2026年初至今累计上涨5.0%，跑赢MSCI中国指数6.2%。医药行业近期明显回调（MSCI中国医疗指数1月15日至今累计下跌9%），特别是创新药板块回调幅度较大（恒生生物科技指数1月15日至今累计下跌13%）。该机构认为，此轮调整原因包括博弈层面行业短期缺乏催化剂，以及行业轮动导致资金流出医药板块。中国创新药资产出海BD持续超预期，MNC对于中国资产的购买范围从单个管线拓宽至平台合作，进一步体现了中国创新药的竞争力。该机构认为，中国的AI制药技术发展迅猛，将涌现一批优秀的创新企业。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","01530","02228","02196","BK1585","LU0561508036.HKD","159992","LU1720050803.USD","LU0307460666.USD","SG9999014674.SGD","02367","BK1617","LU0640798160.USD","09926","IE00B5MMRT66.SGD","LU0588546209.SGD","03933","06978","LU2399975544.HKD","LU1969619763.USD","06160","LU0348783233.USD","BK1100","01789","LU1251922891.USD","LU1115378108.SGD","LU1303224171.USD","LU1794554557.SGD","BK1207","BK1574","SG9999004311.SGD","LU0348784397.USD","LU0348825331.USD","LU0634319403.HKD","BK1197","BK1583","LU2488822045.USD","LU0348827113.USD","LU2328871848.SGD","LU2476274720.SGD","BK1161","LU0348735423.USD","01099","IE00B543WZ88.USD","HK0000165453.HKD","LU1961090484.USD","IE00BPRC5H50.USD","BK1141","BK1515","09688"],"gpt_icon":0},{"id":"2616056538","title":"【券商聚焦】交银国际维持百济神州(06160)买入评级 指4Q25产品销售强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2616056538","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616056538?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:13","pubTimestamp":1772417607,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，百济神州 4Q25泽布替尼销售额11亿，同/环比+38%/+10%，美国销售额8.45亿。在1LCLL患者中，泽布在BTK品类中的份额约占一半、在所有治疗药物中约占1/4。4Q25毛利率同比提升4.7ppts至90.5%，SG&A费用率同比下降7.7ppts，non-GAAP净利润同比大增至2.25亿。公司指引2026年收入62-64亿，GAAP经营费用4749亿，毛利率在80%区间的高位，non-GAAP净利润14-15亿。泽布+索托固定周期疗法首个同机制对照III期近期已启动。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1975682","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2616353805","title":"百济神州盘中异动 快速跳水3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353805","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616353805?lang=zh_cn&edition=full","pubTime":"2026-03-02 09:30","pubTimestamp":1772415053,"startTime":"0","endTime":"0","summary":"2026年03月02日早盘09时30分，百济神州股票出现波动，股价大幅下挫3.07%。截至发稿，该股报186.400港元/股，成交量37.56万股，换手率0.03%，振幅2.91%。机构评级方面，在所有11家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。百济神州股票所在的生物技术行业中，整体跌幅为1.40%。百济神州公司简介：百济神州是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302093053a72f3871&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302093053a72f3871&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1719994722.HKD","BK1161","LU2328871848.SGD","LU1969619763.USD","LU1251922891.USD","06160","LU1770034418.SGD","LU1303224171.USD","BK1588","BK1583","BK1500","LU0588546209.SGD"],"gpt_icon":0},{"id":"2616353892","title":"营收382亿！创新药“一哥”百济神州，全面扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353892","media":"云掌财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616353892?lang=zh_cn&edition=full","pubTime":"2026-03-02 08:57","pubTimestamp":1772413037,"startTime":"0","endTime":"0","summary":"创新药行业，已逐步进入业绩兑现阶段。2月26日晚，百济神州发布2025年业绩快报。然而，面对业绩全面扭亏，市场反应冷淡。财报发布后，百济神州美股两个交易日跌幅超10%。业绩快报显示，百济神州产品收入377.70亿元，同比增长39.9%，主要由百悦泽、安进授权产品及百泽安销售增长驱动。具体来看，2025年百悦泽全球销售额280.67亿元，同比增长48.8%，创历史新高；百泽安全球销售额52.97亿元，同比增长18.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302085726a43fa17d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302085726a43fa17d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","06160"],"gpt_icon":1},{"id":"2616871468","title":"首次实现全年盈利 百济神州2025年营收增长超四成","url":"https://stock-news.laohu8.com/highlight/detail?id=2616871468","media":"经济参考报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616871468?lang=zh_cn&edition=full","pubTime":"2026-03-02 04:50","pubTimestamp":1772398248,"startTime":"0","endTime":"0","summary":"近日，创新药龙头百济神州（688235.SH/06160.HK）发布的2025年度业绩快报显示，公司全年实现营业总收入382.05亿元，同比大幅增长40.4%；实现归属于母公司所有者的净利润达14.22亿元，较上年同期的净亏损49.78亿元实现扭亏为盈。这是百济神州首次实现年度盈利，或标志着这家创新药企迈入可持续盈利的新发展阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603023657828489.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603023657828489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06160","688235","ONC"],"gpt_icon":0},{"id":"2616353806","title":"百济神州(6160.HK)：4Q25产品销售强势、利润端略有波动 2026研发多点开花；维持买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2616353806","media":"交银国际","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616353806?lang=zh_cn&edition=full","pubTime":"2026-03-02 00:00","pubTimestamp":1772380800,"startTime":"0","endTime":"0","summary":"4Q25，泽布替尼延续了美国市场的强劲表现。在1L CLL 患者中，泽布替尼在BTK 品类中的份额约占一半、在所有治疗药物中的份额约占1/4。4Q25 毛利率同比升4.7ppts 至90.5%， SG&A 费用率同比降7.7ppts，non-GAAP 净利润同比大增至2.25亿。2026 年研发多点开花，维持买入：公司管线开发将聚焦四大核心战略领域：1）慢淋：进一步巩固全球领先地位。我们基于2025 年业绩及2026 年指引略微下调2026-27 年盈利预测，下调目标价至229.2 港元/382.0 美元/327.6 元人民币，维持买入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302153135a7307b57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260302153135a7307b57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1770034418.SGD","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","LU1303224171.USD","BK1583","LU1719994722.HKD","LU1251922891.USD","BK1500","BK1588","06160","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2616284869","title":"每周股票复盘：百济神州（688235）2025年净利14.22亿同比增128.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616284869","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616284869?lang=zh_cn&edition=full","pubTime":"2026-03-01 01:16","pubTimestamp":1772298972,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，百济神州报收于257.7元，较上周的279.62元下跌7.84%。本周关注点业绩披露要点：百济神州2025年归属净利润14.22亿元，同比增长128.57%。公司公告汇总：百济神州完成注册地变更，自2025年5月27日起受瑞士法律管辖。公司公告汇总百济神州发布2025年度业绩快报，营业总收入382.05亿元，同比增长40.4%；归属于母公司所有者的净利润14.22亿元，实现扭亏为盈。百悦泽全球销售额280.67亿元，同比增长48.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1161","BK1500","BK0239","LU1969619763.USD","06160","BK1588","LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","LU1770034418.SGD","LU1251922891.USD","LU0588546209.SGD","LU1303224171.USD","688235"],"gpt_icon":0},{"id":"2614789759","title":"首度盈利，股价为何崩了？百济神州叫好不叫座的“盈利魔咒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2614789759","media":"华夏时报网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614789759?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:21","pubTimestamp":1772256083,"startTime":"0","endTime":"0","summary":"2025年，对于素有“创新药一哥”之称的百济神州而言，无疑是载入史册的一年。这份由公司于2月26日晚间交出的年度成绩单，在“归属于母公司所有者的净利润”这一关键指标上，终于迎来了期盼已久的正向数字——14.22亿元。从长达数年的巨额亏损到首次全年盈利，从单纯“烧钱”研发到初步实现自我“造血”，百济神州似乎终于迎来了宣扬已久的“商业化元年”的曙光。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602283657400898.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602283657400898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1719994722.HKD","LU1969619763.USD","LU1251922891.USD","BK4588","LU0588546209.SGD","BK1161","BK1583","06160","BK4526","BK4139","LU1770034418.SGD","BK4585","ONC","LU1303224171.USD","BK1500","688235","BK1588","LU2328871848.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2614890021","title":"百济神州2025年收入53亿美元；勃林格殷格翰宗艾替尼获得FDA特批","url":"https://stock-news.laohu8.com/highlight/detail?id=2614890021","media":"Ofweek维科网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614890021?lang=zh_cn&edition=full","pubTime":"2026-02-28 11:44","pubTimestamp":1772250271,"startTime":"0","endTime":"0","summary":"2025年第四季度，全球总收入达15亿美元，同比增长33%；全年全球总收入达53亿美元，同比增长40%。勃林格殷格翰肿瘤布局新收获。/ 02 /资本信息1）百济神州2025年收入53亿美元2月26日，百济神州发布第四季度财报。2）勃林格殷格翰宗艾替尼获得FDA特批2月26日，FDA通过特批通道批准宗艾替尼用于治疗存在HER2酪氨酸激酶结构域激活突变的不可切除或转移性非鳞状非小细胞肺癌成人患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228114434a7291aed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228114434a7291aed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1161","BK1500","LU1969619763.USD","06160","BK1588","LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","LU1770034418.SGD","LU1251922891.USD","LU0588546209.SGD","LU1303224171.USD"],"gpt_icon":0},{"id":"2614612458","title":"百济神州公布业绩：2025年营收大涨40%达53.4亿美元（约合381亿元）","url":"https://stock-news.laohu8.com/highlight/detail?id=2614612458","media":"生物药大时代","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614612458?lang=zh_cn&edition=full","pubTime":"2026-02-28 00:18","pubTimestamp":1772209099,"startTime":"0","endTime":"0","summary":"2026年2月27日，百济神州公布了其2025年第四季度及全年未经审计的财务业绩。全年总收入达到53.43亿美元，同比增长40%。2025年第四季度，公司经营活动产生的现金流量净额为4.17亿美元，自由现金流达到3.80亿美元。2025年第四季度，百悦泽全球销售额达11亿美元，同比增长38%；全年全球销售额达到39亿美元，同比激增49%。公司预计2026年全年总收入将在62亿美元至64亿美元之间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228002053a4380688&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260228002053a4380688&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160"],"gpt_icon":0},{"id":"2614856787","title":"百济神州迎来“幸福的烦恼” 公司全球研发负责人汪来：“牌”多的时候，不见得每一张都得自己打","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856787","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856787?lang=zh_cn&edition=full","pubTime":"2026-02-27 21:19","pubTimestamp":1772198372,"startTime":"0","endTime":"0","summary":"“我们现在的痛苦和快乐就是管线太强劲，太强劲了以后我们有很多舍不得。你不能slowdown（放慢速度）了，还得快步地往前跑。这里面的确有一个平衡的问题。”2月27日上午，百济神州在线上召开2025年年度业绩路演小组会，公司总裁兼首席运营官吴晓滨说了这样一段话。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602273656980575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656980575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","BK4526","BK0239","LU1251922891.USD","LU0588546209.SGD","LU1719994722.HKD","BK1583","LU1770034418.SGD","BK4588","BK1500","BK4139","LU2328871848.SGD","BK1161","688235","LU1969619763.USD","BK4585","LU1303224171.USD","LU0307460666.USD","BK1588","06160"],"gpt_icon":0},{"id":"2614083875","title":"首度全年盈利的百济神州，与川股百利天恒有一个共同点：都被这些公募基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2614083875","media":"金融投资报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614083875?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:51","pubTimestamp":1772182279,"startTime":"0","endTime":"0","summary":"金融投资报记者贺梦璐“盈利了，但市值却跌破3000亿元。”这或许是百济神州发布2025年度业绩快报后，留给资本市场的最大困惑。金融投资报记者注意到，当投资者将目光转向其股东名单时，一个有意思的巧合开始浮现：那些重仓百济神州的公募基金，同样也对川股百利天恒青睐有加。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602273656715059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1719994722.HKD","BK0239","LU1770034418.SGD","BK1588","BK1583","BK4139","02615","LU1251922891.USD","LU0588546209.SGD","LU2328871848.SGD","BK4585","BK1161","BK4588","91194","06160","LU1303224171.USD","688506","BK1500","688235","LU1969619763.USD","BK4526","ONC","LU0307460666.USD"],"gpt_icon":0},{"id":"2614612108","title":"每日卖空追踪 | 百济神州 02月27日卖空量成交62.71万股，卖空比例为10.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614612108","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614612108?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:30","pubTimestamp":1772181038,"startTime":"0","endTime":"0","summary":"百济神州北京时间02月27日，跌1.08%，卖空量成交62.71万股，较上一交易日减少61.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163541a4367a14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227163541a4367a14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1719994722.HKD","LU1770034418.SGD","BK1500","LU2328871848.SGD","06160","LU1251922891.USD","LU1969619763.USD","LU1303224171.USD","LU0588546209.SGD","LU0307460666.USD","BK1588","BK1161","BK1583"],"gpt_icon":0},{"id":"2614860298","title":"群益证券：维持百济神州(06160)“买入”的评级 首年实现盈利且商业化效果显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2614860298","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614860298?lang=zh_cn&edition=full","pubTime":"2026-02-27 14:28","pubTimestamp":1772173726,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，群益证券发布研报称，维持百济神州“买入”的评级。群益证券主要观点如下：公司业绩快报公司发布2025年业绩快报，实现营业总收入382.1亿元，同比增长40.4%，其中产品收入377.7亿元，YOY+39.9%;实现归母净利润14.2亿元，公司业绩符合预期。其中Q4单季度实现营收106.1亿元，YOY+31.3%,录得归母净利润2.8亿元。另外，百泽安销售53亿元,YOY+19%,主要是在中国新适应获批及入院量增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","06160","688235","ONC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.1459},{"period":"1month","weight":-0.1045},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0878},{"period":"1year","weight":0.1098},{"period":"ytd","weight":0.0318}],"compareEarnings":[{"period":"1week","weight":-0.0377},{"period":"1month","weight":-0.0485},{"period":"3month","weight":-0.0013},{"period":"6month","weight":0.0283},{"period":"1year","weight":0.1359},{"period":"ytd","weight":0.0167}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.027621},{"month":2,"riseRate":0.5,"avgChangeRate":0.032126},{"month":3,"riseRate":0.125,"avgChangeRate":-0.050699},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.07577}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}